Zobrazeno 1 - 10
of 109
pro vyhledávání: '"J. H. Scarffe"'
Autor:
M. Lambert, C. C. Chan, G Chadwick, J. H. Scarffe, David B. Smith, James Chang, Derek Crowther, Ric Swindell, A. McMahon, Heather Anderson
Publikováno v:
Hematological Oncology. 5:213-222
Thirty-three patients with multiple myeloma (11 untreated, 15 refractory and seven relapsed patients) have received vincristine and adriamycin infusion therapy with oral dexamethasone (VAD). The median number of courses received was five. In addition
Autor:
Gordon C Jayson, R. Bloor, G. R. Morgenstern, Ric Swindell, James Chang, C.J. Fraser, Andrew M Wardley, J. H. Scarffe
Publikováno v:
British Journal of Haematology. 110:292-299
Four hundred and twenty-nine patients received myeloablative chemotherapy for solid and haematological malignancies in a bone marrow transplantation unit. Regimens appropriate to the tumour type were administered and haemopoietic reconstitution was a
Autor:
J. H. Scarffe, Mark Dougal, Heather Anderson, J D Robertson, M Zambon, K Nagesh, S N Jowitt, K Mutton
Publikováno v:
British Journal of Cancer
Vaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 pat
Autor:
U. W. Schaefer, J. H. Scarffe, Dietrich W. Beelen, W. D. J. Ryder, Nydia G Testa, C. Kasper, J. Chang, Jan Dürig, K. Nagesh
Publikováno v:
British Journal of Haematology. 104:374-381
Using a limiting dilution assay the frequency of long-term culture-initiating cells (LTC-IC) in the apheresis products following mobilization by granulocyte-colony stimulating factor (G-CSF) with or without chemotherapy from 14 normal donors (ND) for
Autor:
LS Dobson, G. R. Morgenstern, J. H. Scarffe, Derek Crowther, John Radford, W. D. J. Ryder, R. Pettengell, T. Huq, Siow Ming Lee
Publikováno v:
University of Manchester-PURE
British Journal of Cancer
British Journal of Cancer
In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged
Autor:
M. L. Brereton, L. H. Coutinho, Nydia G Testa, S Burdach, G. R. Morgenstern, J. H. Scarffe, James Chang, JALiu Yin, Christine J. Harrison, PJ Darbyshire, T. M. Dexter
Publikováno v:
Bone Marrow Transplantation. 19:969-976
Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rati
Autor:
Janette Beech, Ric Swindell, David J Sherlock, Malcolm R Ranson, Adam Dangoor, Juan W. Valle, J H Scarffe, Siow Ming Lee
Publikováno v:
British Journal of Cancer
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, med
Publikováno v:
Journal of Hospital Infection. 34:171-182
The clinical and molecular epidemiology of two clusters of colonization and infection of patients by glycopeptide-resistant enterococci (GRE) on a leukaemia and bone marrow transplantation unit was studied over a two-and-a half-year period. Thirty-fi
Autor:
L Fitzsimmons, G. R. Morgenstern, D Ryder, Heather Anderson, J. H. Scarffe, GS Wieringa, Malcolm R Ranson, R.I. Young
Publikováno v:
British Journal of Cancer
A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg
Autor:
James Chang, L. H. Coutinho, Demuynck H, S. Bretti, J. H. Scarffe, L. Fitzsimmons, Nydia G Testa, de Campos E, Lord Bi
Publikováno v:
International Journal of Cancer. 59:483-490
Patients with advanced adenocarcinoma of the colon, rectum or pancreas were entered into trials for evaluation of treatment with sequential doses of IL-3 and GM-CSF. They received 0.25 to 5 micrograms IL-3/kg/d for up to 7 days, followed by 1 microgr